MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)

Category Primary study
JournalJournal of clinical oncology
Year 2023
This article has no abstract
Epistemonikos ID: d1bad8d0ef4d7d42bfffb7c85cd3d3ae4df277c6
First added on: Jan 03, 2024